Storia in 2 fonti

Elicio Therapeutics Pancreatic Cancer Study Disappoints - Elicio Therapeutics (NASDAQ:ELTX)

Elicio Therapeutics reports mixed Phase 2 pancreatic cancer results, identifies key patient subgroup benefit, and outlines Phase 3 plans.

Raccontata da

endpoints.news

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo2 g fa

Elicio Therapeutics Pancreatic Cancer Study Disappoints - Elicio Therapeutics (NASDAQ:ELTX)

Elicio Therapeutics reports mixed Phase 2 pancreatic cancer results, identifies key patient subgroup benefit, and outlines Phase 3 plans.

originale

endpoints.news2 g fa

Elicio’s KRAS cancer vaccine fails in Phase 2, shares plummet

Elicio's KRAS cancer vaccine failed to cut recurrence or death vs. observation in a 144-patient Phase 2 trial, plunging shares 70%; company seeks funding for a Phase 3 restricted to R0 patients.

Leggi questa versione → originale

Timeline cronologica

lunedì 15 giugno 2026·endpoints.news
Elicio’s KRAS cancer vaccine fails in Phase 2, shares plummet
Elicio's KRAS cancer vaccine failed to cut recurrence or death vs. observation in a 144-patient Phase 2 trial, plunging shares 70%; company seeks funding for a Phase 3 restricted…
lunedì 15 giugno 2026·benzinga.com
Elicio Therapeutics Pancreatic Cancer Study Disappoints - Elicio Therapeutics (NASDAQ:ELTX)
Elicio Therapeutics reports mixed Phase 2 pancreatic cancer results, identifies key patient subgroup benefit, and outlines Phase 3 plans.

Elicio Therapeutics Pancreatic Cancer Study Disappoints - Elicio Therapeutics (NASDAQ:ELTX)

Elicio’s KRAS cancer vaccine fails in Phase 2, shares plummet

Timeline cronologica

Elicio’s KRAS cancer vaccine fails in Phase 2, shares plummet

Elicio Therapeutics Pancreatic Cancer Study Disappoints - Elicio Therapeutics (NASDAQ:ELTX)

Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug - Elicio Thera